Mirum Pharmaceuticals Inc (NASDAQ:MIRM) reported its fourth quarter and full-year 2025 financial results, delivering a significant top-line beat while its bottom-line performance presented a more complex picture. The rare disease company's earnings release and subsequent market reaction highlight a focus on robust commercial growth against a backdrop of continued investment in its expanding pipeline.
Earnings Performance vs. Estimates
The company's financial results for the final quarter of 2025 showed strong revenue growth, comfortably exceeding analyst expectations. However, the earnings per share figure fell short of estimates, reflecting the company's ongoing investments.
- Revenue: Reported Q4 revenue of $148.9 million surpassed the consensus estimate of approximately $144.6 million. This represents a 50% increase from the $99.4 million reported in Q4 2024.
- Earnings Per Share (EPS): The company reported a non-GAAP EPS loss of $0.11 for the quarter. This missed the analyst estimate for a profit of $0.04 per share.
For the full year 2025, Mirum reported total net product sales of $521.3 million, a 55% increase over the $336.4 million recorded in 2024.
Market Reaction and Price Action
Following the earnings release, the market's reaction has been measured. The stock showed no immediate after-hours movement (0.0% change), suggesting investors are digesting the mixed earnings picture. However, the stock has demonstrated positive momentum in the lead-up to the report, with gains over the past month. This pre-earnings strength may have already priced in some of the positive commercial performance, leaving little room for a significant post-announcement surge despite the revenue beat.
2026 Outlook and Analyst Expectations
A central component of Mirum's report was its financial guidance for the coming year, which provides a tangible benchmark for future performance. The company's outlook appears ambitious when held against current analyst projections.
- Mirum's 2026 Sales Guidance: The company expects global net product sales in the range of $630 million to $650 million.
- Analyst Consensus for 2026: Current analyst estimates project sales of approximately $651.1 million for the full year 2026.
The company's provided range aligns closely with the higher end of market expectations, signaling confidence in continued commercial execution. Notably, Mirum did not provide specific EPS guidance for 2026, while analysts currently model an EPS loss of $0.12 for the year.
Key Business Highlights from the Report
Beyond the financial figures, Mirum's press release emphasized a year of strategic execution and a catalyst-rich near-term future. The most significant takeaways include:
- Commercial Strength: Lead product LIVMARLI achieved net sales of $360.0 million for the year, with U.S. sales growing 69% year-over-year. The company's commercial reach now extends to 33 countries.
- Pipeline Milestones: Management highlighted an expectation for four potentially registrational clinical trial readouts over the next 18 months. The most imminent is topline data from the volixibat VISTAS study in primary sclerosing cholangitis (PSC), expected in the second quarter of 2026.
- Strategic Acquisition: The recent acquisition of Bluejay Therapeutics added brelovitug for hepatitis delta virus (HDV) to the pipeline, with interim data expected in Q2 2026.
- Financial Position: The company ended 2025 with $391.4 million in cash, cash equivalents, and investments, bolstered by a $268.5 million private placement completed in January 2026.
Conclusion
Mirum Pharmaceuticals' Q4 2025 results paint a portrait of a company successfully scaling its commercial operations in rare diseases, as evidenced by a substantial revenue beat and strong annual growth. The EPS miss underscores the significant costs associated with developing its broad clinical pipeline and integrating a new acquisition. The market's muted immediate reaction suggests investors are looking past the quarterly bottom-line to the company's 2026 sales guidance and the density of upcoming clinical catalysts. The guidance, which meets analyst expectations, reinforces the narrative of sustained top-line growth. The coming quarters will be critical as Mirum works to translate its clinical investments into positive data readouts, which are likely to be the next major drivers of shareholder value.
For a detailed look at Mirum's historical earnings and future analyst estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
